Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bioventus reports Q4 revenue decline, focuses on operational efficiency

Bioventus faced revenue challenges in Q4 2022 but demonstrated strength in key segments like Surgical Solutions and international growth.
Actions taken to enhance earnings and financial stability show a commitment to improving performance and regaining investor confidence.
Challenges around revenue decline, gross margin impact, and uncertainty require strategic focus on debt management and operational efficiency.

Bioventus reports Q1 revenue growth, addresses market challenges and opportunities

Bioventus delivered solid Q1 performance with revenue growth and improved EBITDA.
Challenges in the HA market and potential divestitures were key discussion points.
Opportunities lie in revenue growth strategies, cost management, and portfolio optimization.
Overall, Bioventus aims to leverage strengths for sustained growth and profitability.

Bioventus reports Q2 growth, eyes talent acquisition for future

Bioventus showcased financial achievements in Q2 2023, with a focus on improving execution, profitability, and reducing leverage.
Despite revenue decline, the company's adjusted EBITDA increased, driven by strong volume growth in pain treatments and international segment expansion.
Management's confidence in the product portfolio, growth prospects, and talent acquisition bodes well for Bioventus's future performance and strategic direction.

Bioventus reports Q3 resilience, eyes growth in international markets

Bioventus showcased resilience with strong performance in key segments despite revenue decline.
The company's strategic focus on growth drivers and international expansion bodes well for future prospects.
Challenges in certain segments are being addressed with plans for improvement and return to growth.
2024 plans emphasize investments in sales, R&D, and portfolio optimization for sustained growth.

Bioventus reports robust Q4 earnings, sets ambitious goals for 2024

Bioventus delivered strong financial performance in Q4 2023 and outlined ambitious goals for 2024.
The company's focus on revenue growth, operational efficiency, and cash flow improvement reflects a strategic approach to value creation.
While facing debt leverage challenges, Bioventus aims to leverage its strengths and opportunities to drive sustainable growth.
Investors should monitor Bioventus' progress in executing its 2024 priorities and achieving the set financial targets.

Bioventus excels in Q1 2024, focuses on growth and profitability

Bioventus demonstrated robust performance in Q1 2024, driven by revenue growth and margin improvement.
While facing challenges in international growth and operational areas, the company remains optimistic about long-term prospects.
Management's strategic priorities and financial achievements position Bioventus well for future growth and profitability.
Analyst inquiries highlighted key areas for improvement and strategic focus for Bioventus moving forward.

Bioventus excels in Q2 2024, focuses on core growth

Bioventus reported a strong Q2 2024 with revenue growth, improved profitability, and strategic divestment decision
The company aims to drive double-digit revenue and EBITDA growth for the rest of 2024 and into 2025
Despite challenges in Restorative Therapies sales, Bioventus remains focused on core segments for growth
Enhanced financial guidance and operational efficiency position Bioventus for continued success and expansion

Bioventus posts strong Q3 results, eyes growth in medical solutions

Bioventus (BVS) reported robust Q3 results with revenue growth, improved EBITDA, and positive cash flow, reflecting operational strength and financial stability.
Strategic initiatives like the sale of the rehabilitation business demonstrate a focus on optimizing the portfolio and enhancing shareholder value.
While challenges exist in Q4 growth and business transitions, Bioventus remains well-positioned to leverage opportunities in high-demand medical solutions and international markets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Canoo

NovaBay Pharmaceuticals

Understanding the stock market can be a challenging endeavor, yet it offers vast potential for substantial gains, particularly when it comes to penny stocks. Penny stocks, which typically trade below $5 per share, offer an accessible route to market participation, often piquing the interest of investors seeking higher returns with lower capital.

Looking for Undervalued Penny Stocks? Use These Tips

180 Life Sciences 

Take a look at these 3 industries to find penny stocks in.

Penny Stock Investing, 3 High-Growth Industries to Watch

Bioventus Inc. (NASDAQ:BVS ) Q1 2023 Earnings Conference Call May 16, 2023 5:00 PM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Kyle Rose - Canaccord Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to the Bioventus Inc. First Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Dave Crawford, Vice President, Investor Relations.

Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company's management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period ended April 1, 2023, on May 11, 2023.

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction includes a total cash consideration of $85 million, including $35 million in cash at close, a $5 million cash payment deferred 18 months, and $45 million in potential earn-out payments. At the time of close the Company expects to net approximately $30 million after fees and expenses which will be used to repay existing debt.

Bioventus Announces Divestiture of its Wound Business

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

DURHAM, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer (CEO) and as a member of the Board of Directors (board). The board has initiated a comprehensive search process to identify a permanent CEO.

Bioventus Announces CEO Leadership Change

Bioventus Inc. (NASDAQ:BVS ) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Caitlin Cronin - Canaccord Operator Good day. And welcome to the Bioventus Incorporated Fourth Quarter 2022 Earnings Conference Call.

Bioventus Inc. (BVS) Q4 2022 Earnings Call Transcript

DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022.

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday, March 31, 2023, rather than as previously announced to allow additional time to complete its financial statements. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023

DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday, March 30, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023

NEW YORK , March 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period").

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS

LOS ANGELES, CA / ACCESSWIRE / March 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. ("Bioventus" or "the Company") (NASDAQ:BVS) for violations of the federal securities laws. Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on February 11, 2021 (the "IPO") and/or between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"), are encouraged to contact the firm before March 13, 2023.

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm

NEW YORK , March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options

NEW YORK , March 10, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's February 11, 2021 initial public offering (the "IPO" or "Offering"); and/or (ii) between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"), of the important March 13, 2023 lead plaintiff deadline. SO WHAT: If you purchased Bioventus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

BVS DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Bioventus Inc.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)

LOS ANGELES , March 9, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) investors who purchased: (a) Class A common stock pursuant and or traceable to the Offering Documents issued in connection with the Company's February 2021 initial public offering ("IPO"); and/or (b) securities between February 11, 2021 and November 21, 2022 , inclusive (the "Class Period"). If you suffered a loss on your Bioventus investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/bioventus-inc/.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)

Did you lose money on investments in Bioventus? If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (NASDAQ: BVS)

NEW YORK--(BUSINESS WIRE)---- $BVS #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Bioventus Inc.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Bioventus Inc. (BVS) Investors and Encourages Investors to Contact the Firm Before March 13, 2023

NEW YORK , March 3, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period").

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS

BENSALEM, Pa. , March 3, 2023 /PRNewswire/ -- Law Offices of Howard G.

BVS Investors Have Opportunity to Lead Bioventus Inc. Securities Fraud Lawsuit

NEW YORK , March 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's February 11, 2021 initial public offering (the "IPO" or "Offering"); and/or (ii) between February 11, 2021 and November 21, 2022, both dates inclusive (the "Class Period"), of the important March 13, 2023 lead plaintiff deadline. SO WHAT: If you purchased Bioventus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBAL AND LEADING FIRM, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action - BVS

SAN DIEGO , Feb. 28, 2023 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a deadline is coming up on March 13, 2023, in the lawsuit that was filed for certain investors in Bioventus Inc. (NASDAQ: BVS) shares. Investors, with losses in excess of $100,000 with shares of Bioventus Inc. (NASDAQ: BVS) purchased between February 11, 2021, and November 21, 2022, have certain options and there are short and strict deadlines running.

Deadline in Lawsuit for Investors who Lost over $100,000 in shares of Bioventus Inc. between February 2021 and November 2022 announced by Shareholders Foundation

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the “CartiHeal Sellers”) regarding the Company's obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the “Amended Acquisition Agreement”).

Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition

News for Bioventus Stock (BVS)